BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/13/2026 7:25:31 AM | Browse: 4 | Download: 0
 |
Received |
|
2026-03-30 07:40 |
|
Peer-Review Started |
|
2026-03-30 07:45 |
|
First Decision by Editorial Office Director |
|
2026-04-15 09:16 |
|
Return for Revision |
|
2026-04-15 09:16 |
|
Revised |
|
2026-04-28 03:44 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2026-05-21 02:42 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-05-21 08:25 |
|
Articles in Press |
|
2026-05-21 08:25 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-08-06 07:15 |
|
Publish the Manuscript Online |
|
2026-08-13 07:25 |
| ISSN |
2220-6124 (online) |
| Open Access |
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Copyright |
©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Urology & Nephrology |
| Manuscript Type |
Systematic Reviews |
| Article Title |
From kidney to liver: Are sodium–glucose cotransporter-2 inhibitors emerging as metabolic disease modifiers?
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Sydney Mpisa and Jonathan Soldera |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Jonathan Soldera, Tutor, Gastroenterology and Acute Medicine, University of South Wales (in association with Learna Ltd.), University of South Wales, Llantwit Road, Pontypridd, Cardiff CF37 1DL, Cardiff CF37 1DL, United Kingdom. jonathansoldera@gmail.com |
| Key Words |
Hepatocellular carcinoma; Sodium-glucose transporter 2 inhibitors; Metabolic dysfunction-associated steatotic liver disease; Chronic kidney disease; Metabolic disease modification |
| Core Tip |
Sodium-glucose cotransporter-2 inhibitors extend beyond glycaemic control and may modify key pathways of metabolic disease. Evidence from diabetic kidney disease and metabolic dysfunction-associated steatotic liver disease suggests these agents attenuate inflammation and fibrosis, with a potential association with reduced hepatocellular carcinoma incidence. This supports a shift toward integrated, cross-organ metabolic disease modification. |
| Publish Date |
2026-08-13 07:25 |
| Citation |
Mpisa S, Soldera J. From kidney to liver: Are sodium–glucose cotransporter-2 inhibitors emerging as metabolic disease modifiers? World J Nephrol 2026; 15(3): 121652
|
| URL |
https://www.wjgnet.com/2220-6124/full/v15/i3/121652.htm |
| DOI |
https://doi.org/10.5527/wjn.121652 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
